论文部分内容阅读
报道206例1973年1月～1993年7月在Min-nesota大学为医治淋巴瘤而接受自体骨髓移植(ABMT)的患者,继发骨髓增生异常综合征(MDS)的发生率、起病、临床特点及可能的病理生理。206例中发生MDS 9例(其中1例以急性白血病起病)。移植前均接受强烈化疗,中数疗程为14(6～40)个。其中5例接受扩大照射野的放疗。移植前均有治疗导致的骨髓抑制,但无增生异常的形态学特征。ABMT的预处理方案为单独化疗(5例)或环磷酰胺加全身照射(4例)。移植后5年MDS的预期发生率为14.5％±11.6％(95%可信限)。HD和NHL患者
Reported the incidence of secondary myelodysplastic syndrome (MDS) in 206 patients who underwent autologous bone marrow transplantation (ABMT) from Minne Nevsky University from January 1973 to July 1993 for treatment of lymphoma. Features and possible pathophysiology. Ninety-six cases occurred in 206 cases (one of them had acute leukemia). All patients underwent intensive chemotherapy prior to transplantation, with a median of 14 (6 to 40) courses. Five of them received radiotherapy to expand the exposure field. There was bone marrow suppression induced by the treatment before transplantation, but no morphological abnormalities. ABMT pretreatment regimen was chemotherapy alone (n = 5) or cyclophosphamide plus total body irradiation (n = 4). The expected 5-year MDS rate after transplantation was 14.5% ± 11.6% (95% confidence limit). HD and NHL patients